Extent of mediastinal lymphadenectomy during esophagectomy is clearly different between two representative countries of the Eastern and Western world, such as Japan and the Netherlands. In Japan, a clear policy is the standard complete two-or three-field type of lymphadenectomy whereas, in the Netherlands, a limited form is usually carried out. Reasons for these differences can be found in the different types of tumor, 80% of adenocarcinomas in the West and almost 95% of squamous cell cancer in Japan. Moreover, location of the tumors, distally located in the Netherlands whereas, in Japan, the majority are located in the middle and proximal thoracic esophagus. Also, type of neoadjuvant therapy, namely chemoradiotherapy in the Netherlands, and chemotherapy in Japan, are different. Arguments for more extended mediastinal lymphadenectomy are currently challenged in the West, first by the systematic use of chemoradiotherapy as neoadjuvant therapy and, second, the retrospective analysis of large data. According to two studies, the importance of extended lymphadenectomy is shown to be relative and less clear, especially in esophageal adenocarcinomas after neoadjuvant therapy. International efforts such as the TIGER study will help to standardize and find a relationship between the type and location of esophageal cancer, use of neoadjuvant therapy, extent of lymphadenectomy and survival.
| INTRODUCTION
There is no European consensus concerning mediastinal lymphadenectomy during esophageal resection for cancer. This is despite the rapid change of tumor type (more adenocarcinomas), located principally in the distal esophagus and esophagogastric junction (EGJ).
This also ignores advancements in the increased use of neoadjuvant therapies, especially chemoradiotherapy, and the increased use of different types of minimally invasive esophagectomy (MIE). All of these changes have influenced the extent of mediastinal lymphadenectomy in Europe, thereby warranting consensus and a uniform policy. In this article, we point out the significance of these changes and discuss the rationale of the current approach.
| WH AT ARE THE SE CHANGES, ESPECIALLY IN N ORTHERN EUROPE?
Lymphadenectomy has two aims, first to provide a therapeutic survival benefit and, second, to achieve accurate staging of the tumor.
Traditionally, lymph node status (and lymphadenectomy) was considered an important parameter of stage in esophageal cancer (EC) and an independent predictor of survival. Distribution of metastatic lymph nodes (LN) may vary with different factors such as tumor location, tumor histology and biology, tumor invasion depth, length of the tumor (stage) and use of neoadjuvant therapy. 1 Surgical strategy depends on the distribution pattern of nodal metastases, but consensus on the extent of lymphadenectomy differs worldwide.
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| WH AT ARE THE DIFFERENCES IN ESOPHAGEAL CANCER BETWEEN THE NETHERLANDS AND ASIA?
There are several important differences: (i) the incidence is higher in Japan (more than two-fold higher); (ii) the type of tumor is different:
in the Netherlands (NL) and other countries of North Europe, the rate of esophageal adenocarcinoma (Adc) is steadily increasing in incidence to almost 80% of all esophageal cancers (squamous cell cancer [SCC] remains at 19.4%), whereas in Japan, the rate of SCC is 93%, and Adc accounts for only 2.5%; (iii) in NL, distally located EC and esophagogastric junction (EGJ) tumors account for 86.5%, whereas in Japan, tumors located in the upper and middle esophagus account for more than 65%. 4, 5 Furthermore, in Japan, there is an active screening program for esophageal and gastric cancer whereas in the Netherlands and in the rest of Europe this program does not exist. 6 
| INCREASE OF ESOPHAGEAL ADE NOCARCINOMA
In the Netherlands, the rise of adenocarcinoma significantly started during the middle of the 1990s and has progressively increased almost fivefold; this holds especially for male patients and clearly less so for female patients. 7 Factors of influence for these changes may be an increase in obesity, gastroesophageal reflux disease (GERD), alcohol abuse and smoking. 6 These factors have favored the appearance of Barrett's esophagus (BE). In NL, nearly one-third of patients with EC have a body mass index (BMI) of more than 30. In Japan, the majority of patients with SCC have a lower BMI.
| NEOADJUVANT TH ERAPIES
The neoadjuvant therapy of choice in NL and in the majority of the countries in continental Europe is chemoradiotherapy (CRT) according to the CROSS trial (neoadjuvant chemoradiation followed by surgery vs surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus) scheme for stages II and III | 177
The conclusion of this inquiry was that in Europe no consensus existed on the preferred classification system for EC, neither on the use of neoadjuvant therapy for both SCC and Adc, nor on the extent of lymphadenectomy (abdominal and mediastinal) in the different EC situations. However, in Japan, clear guidelines exist for all these points, 4 hence a stark difference.
| EVOLUTION OF ESOPHAGECTOMY IN THE NETHERLANDS (AND E UROPE)
Some 15 years ago, the 5-year survival rate of resected EC patients in Europe was only around 25%; 16 the transhiatal approach was used in 70% of all esophageal resections; a limited two-field mediastinal lymphadenectomy was carried out through the right transthoracic approach; the esophageal resections were not centralized in high-volume centers and mortality was around 10% with a hospital stay of 21 days on average.
Nowadays, the 5-year survival rate in centralized high-volume centers is around 45% (majority of patients have stage III), mortality is 3.5%, hospital stay is 10 days, esophageal resections are centralized in high-volume centers, neoadjuvant therapy is given in stages II and III; and MIE is implemented in 85% of patients with EC.
5,17
Moreover, registration of all resected patients is (anonymously) obligatory with a verification system and special care is paid to the quality of resections per center. 5 Moreover, the Dutch use the American Joint Committee on Cancer (AJCC) classification, at present, the 7th edition. 18 
| WHAT ARE THE REASONS FOR IMPROVEMENT IN SURVIVAL OF EC IN THE NETHERLANDS?
Four Dutch studies show how improvements in survival of EC can have worldwide implications:
1. The HIVEX trial comparing the transhiatal versus the transthoracic approach for distal and EGJ tumors in the era before the implementation of neoadjuvant therapy. 16, 19 2. Use of CRT according to the CROSS trial concerning the use of neoadjuvant therapy. 8, 17 3. Distribution of lymph nodes in EGJ tumors. 20 4. Use of minimally invasive esophagectomy, the TIME study that compared total transthoracic MIE with the open procedure.
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| The HIVEX trial
Long-term follow up of the HIVEX trial (extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus) has indicated that for Siewert tumors type 1, the transthoracic approach has advantages for survival when compared with the transhiatal route; whereas for Siewert type 2 tumors, there are no survival differences between the two approaches. Moreover, the overall survival rate in patients with one to eight metastasized lymph nodes is better using the transthoracic approach than with the transhiatal approach, although it should be noted that if the number of affected nodes exceeded this number, then no differences in survival can be found between the two approaches. Pathological complete response rate was 29% of all primary tumors, being 23% in Adc and 49% in SCC. Furthermore, there were also fewer total numbers of resected nodes and resected positive nodes after CRT followed by surgery than when compared to the group of patients who had surgery alone. 8 In the long term, it is clear that the total group of patients treated by CRT followed by surgery had a progression-free survival rate of 40% vs of 25% in the untreated group. If the two groups are split into both types of cancer, we observe that SCC treated with neoadjuvant therapy shows an important superiority in survival rate compared with the surgery-alone group (60% vs 28%), whereas for Adc this difference was more limited but was still statistically significant (42% vs 28%). subcarinally; whereas in type 2, those located supracarinally were only 0.8%, in the aorta window, 1.7%, and those located subcarinally almost 10%. Moreover, the group of patients with affected LN supracarinally located had a worse prognosis with a survival rate less than 10% after 5 years. 20 This means that for Adc Siewert type 1 and for Adc located in the thoracic esophagus, transthoracic extended or total lymphadenectomy of the mediastinum will need to be carried out after neoadjuvant therapy, whereas for Siewert type 2 only a standard, more limited mediastinal lymphadenectomy up to subcarinal LN should be sufficient.
The TIGER study is a significant attempt to establish consensus on standardizing the type of lymphadenectomy for every specific esophageal tumor. In this study, all lymph node stations will be excised and separately sent for pathological examination. Additional analysis is aimed at identifying patterns of metastases in relation to tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy, thereby providing a roadmap for optimal lymphadenectomy based on its characteristics (Clinicaltrials.gov, trial number NCT03222895).
| Transthoracic open versus minimally invasive esophagectomy
The TIME study constituted a multicentric randomized trial that 
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Moreover, technical complications, including anastomotic leakage
were not different between the two groups. After year 1 and year 3, oncological data-including overall and disease-free survival-was similar between the two groups, entailing a better QoL after 1 year in some scores, such as physical condition and pain, thereby indicating that avoiding thoracotomy is an important advantage of total MIE. 22, 23 Furthermore, these data, with limitation of power of this study for this analysis, show that MIE is an oncologically safe approach.
Based on these studies, surgeons in NL give neoadjuvant CRT in stages 2 and 3 followed by MIE as a first procedure for resection of EC. Concerning the area of anastomosis, 50% are intrathoracic (Ivor Lewis procedure, and the other 50% are cervical anastomosis), although a shift towards more intrathoracic anastomoses is observed. found that the total number of resected nodes was significantly associated with survival only for patients in the surgery-alone arm whereas after CRT the number of resected nodes was not associated with survival. These data importantly question the indication for maximization of mediastinal lymphadenectomy after CRT. 24 Lagergren et al. retrospectively studied a series of esophageal resections between 2000 and 2012 at a large referral center in the UK. They analyzed 606 patients, the majority of patients had Adc, being 83.5% resected by transhiatal or transthoracic approaches.
They studied the extent of lymphadenectomy in relation to all-cause and disease-specific 5-year mortality rates. Four groups were assembled according to nodes resected: 0-10, 11-14, 15-20 and 21-52 LN.
General survival rate was 47% after 5 years. 
| WHAT WE DO DIFFERENTLY IN JAPAN AND THE NETHERLANDS REGARDING E C?
In Japan, upper and middle thoracic SCC constitute 65% of all EC whereas in NL the numbers are approximately 12.3% (SCC 75% and 25% Adc). Tumors in upper and middle thoracic locations mostly metastasize to cervical and high mediastinal areas. Therefore, in Japan, for stage 2 and 3, surgeons advise the use of neoadjuvant chemotherapy followed by three-field lymphadenectomy. 4 However, in Europe, for patients with these tumors, neoadjuvant CRT or chemotherapy followed by total or extended two-field lymphadenectomy is done. Regarding lower thoracic localized EC, in Japan, 24.2% are all SCC, whereas in the Netherlands, 60% of EC are localized in this region (being 85.3% Adc and 14.6% SCC). 4, 5 Concerning these lower thoracic cancers, in Japan neoadjuvant chemotherapy is used in stages 2 and 3, being the extension of mediastinal lymphadenectomy under discussion: two-field is the rule, three-field lymphadenectomy is exceptional, because LN metastasis in the cervical area is clearly less frequent. In Europe, neoadjuvant CRT followed by resection (Ivor Lewis approach is increasingly used) with standard or extended mediastinal lymphadenectomy is used. | 179 tumors, the rest SCC at only 4.3%). However, in Japan, only 4.5% of SCC are "abdominally" located and less than 3% of all EC are Adc.
Concerning neoadjuvant therapy, surgeons in Japan use chemotherapy, whereas surgeons in Europe give CRT or chemotherapy for Siewert types 1 and 2.
Definitions for EGJ tumors also differ between Europe and Japan. In Japan, esophagogastric junction is defined as a tumor localized in an area within 2 cm above and below the EGJ junction. Also, esophagogastric junction cancer (abdominal esophageal carcinoma) has its center located in this region. 4 In Europe, the AJCC 7th edition defines this tumor as including cancers whose epicenter is in the distal thoracic esophagus, esophagogastric junction or within the proximal 5 cm of the stomach (cardia) that extend into the esophagogastric junction or distal esophagus. Seen in this way, types 1 and 2 are considered as esophageal cancers whereas type 3 is gastric. The hurdle in this operation is the difficult anastomosis. There are different possibilities: manual anastomosis, end-to-side anastomosis using a conventional or specific circular Orvilâ stapler (Medtronic, Medline Industries inc., Arnhem, the Netherlands) and, finally, the linear stapler to carry out a side-to-side anastomosis. 26, 27 The possibility of carrying out the anastomosis very high in the thoracic cavity is more difficult and will be facilitated by the use of the ergonomy of the robot. 28 The TIGER study is a significant attempt to establish a consensus on standardizing the type of lymphadenectomy for every specific esophageal tumor. Participation in this study should be encouraged.
| IMPLEMENTATION OF MIE
In Europe, the combination of more standardized mediastinal lymphadenectomy in combination with a better selection of esophageal cancer patients for surgery and proper neoadjuvant therapy will probably help to increase the survival rate of esophageal cancer in the coming years.
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